CN1238341C - 1α－羟基－25－烯－维生素D及其类似物和应用 - Google Patents

1α－羟基－25－烯－维生素D及其类似物和应用 Download PDF

Info

Publication number
CN1238341C
CN1238341C CNB998067873A CN99806787A CN1238341C CN 1238341 C CN1238341 C CN 1238341C CN B998067873 A CNB998067873 A CN B998067873A CN 99806787 A CN99806787 A CN 99806787A CN 1238341 C CN1238341 C CN 1238341C
Authority
CN
China
Prior art keywords
formula
alpha
hydroxy
alkyl
side chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB998067873A
Other languages
English (en)
Chinese (zh)
Other versions
CN1303368A (zh
Inventor
查尔斯·W·毕晓普
乔伊斯·C·克努森
斯蒂芬·斯特拉格内尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bone Care International Inc
Original Assignee
Bone Care International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bone Care International Inc filed Critical Bone Care International Inc
Publication of CN1303368A publication Critical patent/CN1303368A/zh
Application granted granted Critical
Publication of CN1238341C publication Critical patent/CN1238341C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CNB998067873A 1998-05-29 1999-05-28 1α－羟基－25－烯－维生素D及其类似物和应用 Expired - Fee Related CN1238341C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/087,439 1998-05-29
US09/087,439 US5972917A (en) 1998-05-29 1998-05-29 1 α-hydroxy-25-ene-vitamin D, analogs and uses thereof

Publications (2)

Publication Number Publication Date
CN1303368A CN1303368A (zh) 2001-07-11
CN1238341C true CN1238341C (zh) 2006-01-25

Family

ID=22205199

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB998067873A Expired - Fee Related CN1238341C (zh) 1998-05-29 1999-05-28 1α－羟基－25－烯－维生素D及其类似物和应用

Country Status (14)

Country Link
US (1) US5972917A (de)
EP (1) EP1082298B1 (de)
JP (1) JP2002516307A (de)
CN (1) CN1238341C (de)
AT (1) ATE253554T1 (de)
AU (1) AU754211B2 (de)
BR (1) BR9910672A (de)
CA (1) CA2333270A1 (de)
DE (1) DE69912598T2 (de)
DK (1) DK1082298T3 (de)
ES (1) ES2211107T3 (de)
IL (1) IL139353A (de)
PT (1) PT1082298E (de)
WO (1) WO1999061418A2 (de)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8911971B2 (en) 2011-02-17 2014-12-16 Purecircle Usa Inc. Glucosyl stevia composition
US8981081B2 (en) 2010-03-12 2015-03-17 Purecircle Usa Inc. High-purity steviol glycosides
US8993269B2 (en) 2011-02-17 2015-03-31 Purecircle Usa Inc. Glucosyl stevia composition
US9029426B2 (en) 2010-12-13 2015-05-12 Purecircle Sdn Bhd Highly soluble Rebaudioside D
US9107436B2 (en) 2011-02-17 2015-08-18 Purecircle Sdn Bhd Glucosylated steviol glycoside as a flavor modifier
US9243273B2 (en) 2012-05-22 2016-01-26 Purecircle Sdn Bhd Method for making rebaudioside X
US9386797B2 (en) 2011-02-17 2016-07-12 Purecircle Sdn Bhd Glucosyl stevia composition
US9392799B2 (en) 2011-02-17 2016-07-19 Purecircle Sdn Bhd Glucosyl stevia composition
US9427006B2 (en) 2011-02-10 2016-08-30 Purecircle Sdn Bhd Highly soluble Stevia sweetener
US9474296B2 (en) 2011-02-17 2016-10-25 Purecircle Sdn Bhd Glucosyl stevia composition
US9510611B2 (en) 2010-12-13 2016-12-06 Purecircle Sdn Bhd Stevia composition to improve sweetness and flavor profile
US12037356B2 (en) 2010-03-12 2024-07-16 Purecircle Usa Inc. Methods of preparing steviol glycosides and uses of the same

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020183288A1 (en) * 1995-04-03 2002-12-05 Bone Care International, Inc. Method for treating and preventing hyperparathyroidism
US6242434B1 (en) * 1997-08-08 2001-06-05 Bone Care International, Inc. 24-hydroxyvitamin D, analogs and uses thereof
US20040043971A1 (en) * 1995-04-03 2004-03-04 Bone Care International, Inc. Method of treating and preventing hyperparathyroidism with active vitamin D analogs
US20020128240A1 (en) * 1996-12-30 2002-09-12 Bone Care International, Inc. Treatment of hyperproliferative diseases using active vitamin D analogues
US20030129194A1 (en) * 1997-02-13 2003-07-10 Bone Care International, Inc. Targeted therapeutic delivery of vitamin D compounds
US6392071B1 (en) * 1997-03-17 2002-05-21 Wisconsin Alumni: Research Foundation 26,27-homologated-20-EPI-2-alkylidene-19-nor-vitamin D compounds
US6087350A (en) 1997-08-29 2000-07-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Use of pretreatment chemicals to enhance efficacy of cytotoxic agents
AUPP405098A0 (en) * 1998-06-12 1998-07-02 Access Pharmaceuticals Australia Pty Limited Novel methods of preparation of vitamin b12 derivatives suitable for conjugation to pharmaceuticals
DE60024118T2 (de) * 1999-09-20 2006-07-27 Eli Lilly And Co., Indianapolis Verwendung einer parathyroidhormone zur reduktion des krebsrisikos
WO2002006218A2 (en) * 2000-07-18 2002-01-24 Bone Care International, Inc. STABILIZED 1α-HYDROXY VITAMIN D
US6465446B1 (en) * 2001-03-12 2002-10-15 John C. Dykstra Treatment of dermatitis by the topical application of Δ5-androstene-3β-ol-7,17 dione and metabolizable precursors thereof
US7129230B2 (en) 2001-03-12 2006-10-31 Nestec S.A. Method and product for treating cancer in pets
WO2003047595A1 (en) * 2001-12-03 2003-06-12 Novacea, Inc. Pharmaceutical compositions comprising active vitamin d compounds
AU2002360015A1 (en) * 2001-12-26 2003-07-15 Chugai Seiyaku Kabushiki Kaisha 2-substituted vitamin d derivatives
NZ534863A (en) * 2002-03-29 2005-05-27 Wisconsin Alumni Res Found Method of synthesizing 1 alpha-hydroxy-2-methylene-19-nor- vitamin D compounds
US7148211B2 (en) * 2002-09-18 2006-12-12 Genzyme Corporation Formulation for lipophilic agents
US20040058895A1 (en) * 2002-09-18 2004-03-25 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
US20040053895A1 (en) * 2002-09-18 2004-03-18 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
MXPA05003499A (es) * 2002-10-23 2005-06-17 Leo Pharma As Analogos de vitamina d, composiciones que los comprenden y su uso.
WO2004047673A2 (en) * 2002-11-21 2004-06-10 Novacea, Inc. Treatment of liver disease with active vitamin d compounds
JP2007501865A (ja) * 2003-06-11 2007-02-01 ノバセア インコーポレイティッド 放射線治療薬および放射線治療と併用した、活性ビタミンｄ化合物による癌の治療法
EP1631297A4 (de) * 2003-06-11 2007-09-05 Novacea Inc Behandlung von immunvermittelten erkrankungen mit aktiven vitamin d verbindungen allein oder in kombination mit anderen therapeutika
SG110107A1 (en) 2003-09-24 2005-04-28 Bioxell Spa Compound and use in treatment
US7214671B2 (en) * 2004-02-19 2007-05-08 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D3 for the prophylaxis of bone diseases
US7713951B2 (en) * 2004-04-09 2010-05-11 Wisconsin Alumni Research Foundation 2-alkylidene-18,19-dinor-vitamin D compounds
US20070275934A1 (en) * 2004-05-10 2007-11-29 Curd John G Treatment of pancreatic cancer with active vitamin d compounds in combination with other treatments
US7094775B2 (en) * 2004-06-30 2006-08-22 Bone Care International, Llc Method of treating breast cancer using a combination of vitamin D analogues and other agents
JP5449767B2 (ja) 2005-04-25 2014-03-19 サイトクロマ インコーポレイテッド １α，２５−ジヒドロキシビタミンＤ３の低血漿カルシウム上昇性１６，２３−ジエン−２５−オキシムアナログ
JP5155170B2 (ja) * 2005-10-06 2013-02-27 ネステク ソシエテ アノニム 免疫を改善するためのプロバイオティックエンテロコッカス
US20100009949A1 (en) * 2006-03-24 2010-01-14 Bioxell S.P.A. Novel method
EA201691980A1 (ru) 2009-01-27 2017-07-31 БЕРГ ЭлЭлСи Способы уменьшения побочных эффектов, связанных с химиотерапией
SG178382A1 (en) 2009-08-14 2012-04-27 Berg Biosystems Llc Vitamin d3 and analogs thereof for treating alopecia
KR102125424B1 (ko) * 2010-03-29 2020-06-22 사이토크로마 인코포레이티드 부갑상선 수준을 낮추기 위한 방법 및 조성물
WO2014179737A2 (en) 2013-05-03 2014-11-06 The General Hospital Corporation Assays and methods of treatment relating to vitamin d insufficiency
US9052308B2 (en) 2011-01-07 2015-06-09 The General Hospital Corporation Assays and methods of treatment relating to vitamin D insufficiency
EP2661632B1 (de) 2011-01-07 2018-03-07 The General Hospital Corporation Assays und verfahren für eine behandlung im zusammenhang mit vitamin-d-mangel
DE102011112532B4 (de) 2011-09-05 2019-03-21 Audi Ag Prüfeinrichtung und Verfahren zum Prüfen von Batteriezellen
US9370527B2 (en) * 2012-12-28 2016-06-21 The Regents Of The University Of Michigan Amelioration of intestinal fibrosis and treatment of Crohn's disease
CN105492081A (zh) 2013-05-29 2016-04-13 博格有限责任公司 使用维生素d预防或减轻化疗诱发的脱发

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4202829A (en) * 1978-01-05 1980-05-13 Wisconsin Alumni Research Foundation Process for preparing 1α-hydroxylated compounds
US4195027A (en) * 1978-01-16 1980-03-25 Wisconsin Alumni Research Foundation Process for preparing 1α-hydroxylated compounds
US4260549A (en) * 1979-05-21 1981-04-07 Wisconsin Alumni Research Foundation Process for preparing 1α-hydroxylated compounds
US4225596A (en) * 1978-10-13 1980-09-30 Wisconsin Alumni Research Foundation Method for treating calcium imbalance and improving calcium absorption in mammals
JPS5626820A (en) * 1979-08-10 1981-03-16 Chugai Pharmaceut Co Ltd Immunosuppressing agent
US4234495A (en) * 1979-09-10 1980-11-18 Wisconsin Alumni Research Foundation Process for preparing 1α-hydroxyvitamin D compounds from 1α-hydroxy-3,5-cyclovitamin D compounds
DK160817C (da) * 1979-10-23 1991-10-07 Teijin Ltd Fremgangsmaade til fremstilling af vitamin d3 forbindelser
JPS57149224A (en) * 1981-03-13 1982-09-14 Chugai Pharmaceut Co Ltd Tumor-suppressing agent
US4652405A (en) * 1981-08-28 1987-03-24 Hoffman-La Roche Inc. Synthesis of 1α,25-dihydroxy-24R-fluorocholecalciferol and 1α,25-dihydroxy-24S-fluorocholecalciferol
US4689180A (en) * 1984-01-30 1987-08-25 Wisconsin Alumni Research Foundation 1α,25-dihydroxy-22Z-dehydroxyvitamin D compound
US4481198A (en) * 1984-02-13 1984-11-06 Wisconsin Alumni Research Foundation Vitamin D metabolism inhibitor
US4554106A (en) * 1984-11-01 1985-11-19 Wisconsin Alumni Research Foundation Method for preparing 1α-hydroxyvitamin D compounds
US4555364A (en) * 1984-11-01 1985-11-26 Wisconsin Alumni Research Foundation Method for preparing 1-hydroxyvitamin D compounds
EP0184112B1 (de) * 1984-11-27 1990-05-09 Chugai Seiyaku Kabushiki Kaisha Vitamin D-Derivate und Verfahren zu deren Herstellung
US4749710A (en) * 1985-05-01 1988-06-07 Hoffmann-La Roche Inc. Immunosuppressive agents
JP2711161B2 (ja) * 1988-04-21 1998-02-10 レオ・ファーマシューティカル・プロダクツ・リミテッド・エイ／エス（レーベンス・ケミスケ・ファブリック・プロデュクチオンスアクチーセルスカブ） 新規ビタミンｄ類似体
US5250523A (en) * 1988-04-29 1993-10-05 Wisconsin Alumni Research Foundation Side chain unsaturated 1α-hydroxyvitanim D homologs
ATE90075T1 (de) * 1988-12-12 1993-06-15 Duphar Int Res Verfahren zur photochemischen umwandlung von tachysterol-derivaten in praevitamin d-derivate und von transvitamin d-derivaten in cisvitamin d- derivate.
US5098899A (en) * 1989-03-06 1992-03-24 Trustees Of Boston University Method for therapeutically treating psoriatic arthritis using vitamin D analogues and metabolites
CA1333616C (en) * 1989-03-09 1994-12-20 Hector F. Deluca 19-nor-vitamin d compounds
US5063221A (en) * 1989-04-05 1991-11-05 Chugai Seiyaku Kabushiki Kaisha Treatment for hyperparathyroidism with use of vitamin d derivatives
GB8915770D0 (en) * 1989-07-10 1989-08-31 Leo Pharm Prod Ltd Chemical compounds
US5518725A (en) * 1989-09-25 1996-05-21 University Of Utah Research Foundation Vaccine compositions and method for induction of mucosal immune response via systemic vaccination
JP2505313B2 (ja) * 1989-09-25 1996-06-05 ユニバーシティ オブ ユタ リサーチ ファウンデーション Ｔ細胞リンフォカインの産生を誘発する組成物でのステロイドホルモンの使用
US5562910A (en) * 1989-09-25 1996-10-08 University Of Utah Research Foundation Vaccine compositions and method for enhancing an immune response
US5260290A (en) * 1990-02-14 1993-11-09 Wisconsin Alumni Research Foundation Homologated vitamin D2 compounds and the corresponding 1α-hydroxylated derivatives
GB9007236D0 (en) * 1990-03-30 1990-05-30 Leo Pharm Prod Ltd Chemical compounds
ES2073661T3 (es) * 1990-04-27 1995-08-16 Duphar Int Res Metodo para la isomerizacion fotoquimica de compuestos organicos bajo la influencia de un fotosensibilizador.
DE69327480T2 (de) * 1992-02-27 2002-11-21 Duphar International Research B.V., Weesp Verfahren zur Herstellung 9-Beta,10-Alpha-5,7-Dien-Steroiden
DE4220757A1 (de) * 1992-06-24 1994-01-05 Schering Ag Derivate in der Vitamin D-Reihe mit Modifikationen in der 20-Position, Verfahren zu ihrer Herstellung, Zwischenprodukte für dieses Verfahren, diese Derivate enthaltende pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln
GB9220439D0 (en) * 1992-09-28 1992-11-11 Leo Pharm Prod Ltd Chemical compounds
US5753638A (en) * 1992-10-07 1998-05-19 Hoffmann-La Roche Inc. Method of treating hyperproliferative skin disease with Vitamin D3 fluorinated analogs
GB9223061D0 (en) * 1992-11-04 1992-12-16 Leo Pharm Prod Ltd Chemical compounds
US5449668A (en) * 1993-06-04 1995-09-12 Duphar International Research B.V. Vitamin D compounds and method of preparing these compounds
US5665387A (en) * 1994-09-01 1997-09-09 K.U. Leuven Research & Development Methods and compositions for primary and secondary prevention of autoimmune diabetes
US5559107A (en) * 1994-10-20 1996-09-24 Gates; Stephen Regulation of immune response
NZ307549A (en) * 1995-06-14 1999-11-29 Schering Ag Novel vitamin d derivatives with c-25 substituents, process for their preparation, intermediate products and their use in preparing medicaments
GB9524812D0 (en) * 1995-12-05 1996-02-07 Leo Pharm Prod Ltd Chemical compounds
US5716946A (en) * 1996-02-13 1998-02-10 Wisconsin Alumni Research Foundation Multiple sclerosis treatment

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8981081B2 (en) 2010-03-12 2015-03-17 Purecircle Usa Inc. High-purity steviol glycosides
US12037356B2 (en) 2010-03-12 2024-07-16 Purecircle Usa Inc. Methods of preparing steviol glycosides and uses of the same
US9510611B2 (en) 2010-12-13 2016-12-06 Purecircle Sdn Bhd Stevia composition to improve sweetness and flavor profile
US9029426B2 (en) 2010-12-13 2015-05-12 Purecircle Sdn Bhd Highly soluble Rebaudioside D
US9427006B2 (en) 2011-02-10 2016-08-30 Purecircle Sdn Bhd Highly soluble Stevia sweetener
US9107436B2 (en) 2011-02-17 2015-08-18 Purecircle Sdn Bhd Glucosylated steviol glycoside as a flavor modifier
US9386797B2 (en) 2011-02-17 2016-07-12 Purecircle Sdn Bhd Glucosyl stevia composition
US9392799B2 (en) 2011-02-17 2016-07-19 Purecircle Sdn Bhd Glucosyl stevia composition
US8911971B2 (en) 2011-02-17 2014-12-16 Purecircle Usa Inc. Glucosyl stevia composition
US9474296B2 (en) 2011-02-17 2016-10-25 Purecircle Sdn Bhd Glucosyl stevia composition
US9055761B2 (en) 2011-02-17 2015-06-16 Purecircle Usa Inc. Glucosyl Stevia composition
US11844365B2 (en) 2011-02-17 2023-12-19 Purecircle Sdn Bhd Glucosyl Stevia composition
US8993269B2 (en) 2011-02-17 2015-03-31 Purecircle Usa Inc. Glucosyl stevia composition
US9243273B2 (en) 2012-05-22 2016-01-26 Purecircle Sdn Bhd Method for making rebaudioside X

Also Published As

Publication number Publication date
CA2333270A1 (en) 1999-12-02
ES2211107T3 (es) 2004-07-01
CN1303368A (zh) 2001-07-11
EP1082298A2 (de) 2001-03-14
DK1082298T3 (da) 2004-02-16
US5972917A (en) 1999-10-26
IL139353A0 (en) 2001-11-25
EP1082298B1 (de) 2003-11-05
BR9910672A (pt) 2001-01-30
AU754211B2 (en) 2002-11-07
AU4544599A (en) 1999-12-13
PT1082298E (pt) 2004-03-31
WO1999061418A2 (en) 1999-12-02
WO1999061418A3 (en) 2000-03-23
DE69912598D1 (de) 2003-12-11
JP2002516307A (ja) 2002-06-04
IL139353A (en) 2005-08-31
DE69912598T2 (de) 2004-09-23
ATE253554T1 (de) 2003-11-15

Similar Documents

Publication Publication Date Title
CN1238341C (zh) 1α－羟基－25－烯－维生素D及其类似物和应用
CN1379675A (zh) 24－羟基－维生素d及其类似物和应用
CN100345547C (zh) 使用延迟和/或持续释放的维生素d制剂治疗前列腺疾病的方法
JP6236657B2 (ja) ビタミンｄ化合物およびワックス状担体を含有する制御放出性経口組成
US6521608B1 (en) Vitamin D and its analogs in the treatment of tumors and other hyperproliferative disorders
JP5952363B2 (ja) ビタミンｄ療法のための方法および化合物
CN1032256C (zh) 1α，24二羟维生素D2的制备及其应用方法
CN1758916A (zh) 应用维生素d2或d4化合物治疗或预防甲状旁腺功能亢进的方法
CA2797537C (en) Use of 25-hydroxyvitamin d compound for reducing parathyroid levels
CN1554351A (zh) 包含活性维生素d化合物的药物组合制剂及其应用
EP3335712A1 (de) Verfahren zur sicheren und effektiven behandlung und vorbeugung von sekundärem hyperparathyroidismus bei chronischer nierenerkrankung
MX2010008904A (es) Uso de 25-hidroxi-vitamina d3 para afectar la fisiologia muscular humana.
CN1646137A (zh) 治疗和预防甲状旁腺机能亢进的方法
CN1186435A (zh) 维生素d4衍生物在治疗癌症中的应用
JP2007523162A (ja) ２‐メチレン‐１９‐ノル‐２０（Ｓ）‐１α，２５‐ジヒドロキシビタミンＤ３の骨疾患の予防のための使用
Beltrame et al. Vitamin D supplementation in patients after bariatric surgery
MXPA00011215A (en) 1&agr;-HYDROXY-25-ENE-VITAMIN D, ANALOGS AND USES THEREOF

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20060125

Termination date: 20110528